Repligen Corporation (NASDAQ:RGEN - Get Free Report) has received a consensus rating of "Moderate Buy" from the fourteen analysts that are covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation, nine have given a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $170.25.
A number of equities research analysts have commented on RGEN shares. Roth Mkm assumed coverage on shares of Repligen in a report on Friday, April 17th. They issued a "buy" rating and a $160.00 price target for the company. Wells Fargo & Company decreased their target price on shares of Repligen from $190.00 to $180.00 and set an "overweight" rating for the company in a research report on Wednesday, February 25th. Canaccord Genuity Group lowered their target price on shares of Repligen from $165.00 to $145.00 and set a "hold" rating on the stock in a report on Monday, April 20th. Barclays dropped their price target on shares of Repligen from $175.00 to $145.00 and set an "overweight" rating on the stock in a research report on Tuesday, April 14th. Finally, KeyCorp reaffirmed an "overweight" rating on shares of Repligen in a research report on Wednesday, February 25th.
Check Out Our Latest Analysis on Repligen
Hedge Funds Weigh In On Repligen
Several large investors have recently added to or reduced their stakes in RGEN. Measured Wealth Private Client Group LLC bought a new position in Repligen in the 3rd quarter valued at about $29,000. Bayforest Capital Ltd bought a new position in Repligen in the 4th quarter valued at about $32,000. Rachor Investment Advisory Services LLC bought a new position in Repligen in the 4th quarter valued at about $33,000. Los Angeles Capital Management LLC bought a new position in Repligen in the 4th quarter valued at about $36,000. Finally, CWM LLC lifted its position in Repligen by 67.2% in the 3rd quarter. CWM LLC now owns 336 shares of the biotechnology company's stock valued at $45,000 after acquiring an additional 135 shares in the last quarter. Institutional investors own 97.64% of the company's stock.
Repligen Trading Down 0.9%
NASDAQ:RGEN opened at $117.20 on Friday. The company has a current ratio of 8.37, a quick ratio of 7.12 and a debt-to-equity ratio of 0.26. The stock has a market capitalization of $6.61 billion, a price-to-earnings ratio of 137.88, a PEG ratio of 2.31 and a beta of 1.09. The firm has a fifty day simple moving average of $121.56 and a two-hundred day simple moving average of $144.73. Repligen has a 12 month low of $109.50 and a 12 month high of $175.77.
Repligen (NASDAQ:RGEN - Get Free Report) last posted its quarterly earnings results on Tuesday, February 24th. The biotechnology company reported $0.49 EPS for the quarter, topping analysts' consensus estimates of $0.44 by $0.05. The business had revenue of $197.91 million during the quarter, compared to analysts' expectations of $192.23 million. Repligen had a net margin of 6.62% and a return on equity of 4.71%. The business's quarterly revenue was up 18.1% on a year-over-year basis. During the same period last year, the company posted $0.44 earnings per share. Repligen has set its FY 2026 guidance at 1.930-2.010 EPS. Analysts expect that Repligen will post 1.97 EPS for the current fiscal year.
About Repligen
(
Get Free Report)
Repligen Corporation NASDAQ: RGEN is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen's offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.
The company's core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Repligen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Repligen wasn't on the list.
While Repligen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead.
This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
